KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Change in Cash: 2018-2025

Historic Change in Cash for Moderna (MRNA) over the last 8 years, with Sep 2025 value amounting to -$147.0 million.

  • Moderna's Change in Cash rose 82.35% to -$147.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$513.0 million, marking a year-over-year increase of 60.72%. This contributed to the annual value of -$999.0 million for FY2024, which is 245.67% down from last year.
  • Moderna's Change in Cash amounted to -$147.0 million in Q3 2025, which was up 57.39% from -$345.0 million recorded in Q2 2025.
  • Over the past 5 years, Moderna's Change in Cash peaked at $2.8 billion during Q1 2021, and registered a low of -$2.2 billion during Q2 2022.
  • Moreover, its 3-year median value for Change in Cash was -$147.0 million (2025), whereas its average is -$189.4 million.
  • As far as peak fluctuations go, Moderna's Change in Cash surged by 1,705.77% in 2021, and later tumbled by 1,450.93% in 2022.
  • Moderna's Change in Cash (Quarterly) stood at $1.3 billion in 2021, then crashed by 86.45% to $176.0 million in 2022, then tumbled by 114.20% to -$25.0 million in 2023, then spiked by 1,228.00% to $282.0 million in 2024, then surged by 82.35% to -$147.0 million in 2025.
  • Its last three reported values are -$147.0 million in Q3 2025, -$345.0 million for Q2 2025, and -$303.0 million during Q1 2025.